LUNGMAP

Please Note:

This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid Master Protocol (Lung-MAP). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes non-match sub-studies which will include all screened patients not eligible for any of the biomarker-driven sub-studies.

Available Sites

• Missouri Baptist Medical Center
• Missouri Baptist Outpatient Center – Sunset Hills
• Missouri Baptist Sullivan Hospital
• Sainte Genevieve County Memorial Hospital
• Parkland Health Center - Farmington

Contact Person(s)

• Patricia Kulla, 314-996-4617

View More Information - This link will take you to clinicaltrials.gov for specific study information including eligibility criteria. A full list of participating institutions can also be found on this page.